A 33-year-old woman developed progressive ovarian cancer resistant to classical chemotherapy agents. We performed a bone marrow allograft after a myeloablative regimen. During hematological recovery, she developed acute graft-versus-host disease (GVHD). From this time her tumor diminished progressively. One year post transplant she has limited chronic liver GVHD and is still free of disease. The complete remission of advanced ovarian cancer was probably related to the GVHD which might therefore provide a new treatment option for this disease. Bone Marrow Transplantation (2000) 25, 681-682. Keywords: ovarian cancer; allograft transplantation; graft-versus-host disease
The graft-versus-leukemia (GVL) effect has been reported in hematological malignancies after allogeneic treatments. This immunological effect has been recently described in patients with solid tumors after allogeneic bone marrow transplantation (graft-versus-tumor effect). [1] [2] [3] Ovarian carcinoma represents an additional target for this type of immunotherapy. 4 In this context, we report the first case of a patient who achieved a complete response after allogeneic bone marrow transplantation for ovarian cancer.
Case report
A 33-year-old woman was diagnosed with ovarian cancer in May 1995. She presented with a serous papillary adenocarcinoma stage III C (FIGO). A partial remission was achieved after six chemotherapy courses (PAC: doxorubicin 240 mg total dose received (TDR), cyclophosphamide 6400 mg TDR, cisplatin 720 mg TDR). After this first-line chemotherapy complete surgery was performed, followed by intraperitoneal chemotherapy (doxorubicin 5 mg and cisplatin 25 mg once daily for 5 consecutive days). She relapsed 10 months later in September 1997. At this time she presented with an occlusive syndrome, subcutaneous tumor nodules and pulmonary metastases. This relapse was confirmed by an elevation of CA125 (164 U) and tomodensitometric examination. She was treated with seven courses of paclitaxel 1765 mg TDR and carboplatin 3140 mg TDR. A transitory partial response was obtained after four courses, but was followed by disease progression. According to our experience in autologous transplantation, the prognosis of the patient was poor and intensive chemotherapy followed by autologous peripheral blood stem cell transplantation was unlikely to be able to cure the disease. 5 Because of the good performance status of the patient, a bone marrow allograft was proposed with an HLA-identical, sex mismatched adult sibling.
Before the allograft procedure the patient presented with abdominal tumor nodules, a progression of pulmonary metastatic lesions and the elevation of CA125 (169 U). The conditioning regimen consisted of myleran 4 mg/kg daily for 4 consecutive days and cyclophophamide 50 mg/kg daily for 4 consecutive days. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. Complete hematological recovery was obtained, with full cytogenetic chimerism at day 30. Acute grade III GVHD (Glucksberg) involving the skin and digestive tract started at day 28, which was successfully treated with corticotherapy followed by anti-R-IL 2 (leukotak). Concurrently, clinical symptoms disappeared followed by normalization of CA125 on day 60 and CT scan remission on day 90. Laparotomy/laparoscopy was not indicated for treatment or for evaluation because clinical examinations showed the disappearance of subcutaneous nodules and CT scan showed that the tumor was not detectable. Immunosuppression was discontinued at day 90 while the patient was in complete remission. The patient was seen each month for clinical and CA125 evaluation. A CT scan was repeated every 2-3 months. Six months after allograft, chronic liver GVHD was documented by biopsy and required new immunosuppression. One year after trans-plantion the patient presents limited chronic liver GVHD and is still free of documented disease.
Discussion
This report suggests the good tolerance of allogeneic bone marrow transplantation in advanced ovarian cancer.
The conditioning regimen may have contributed to disease regression. However, no regression was observed until the onset of GVHD, 4 weeks after the allograft. From this time, we observed a clear association between the regression of the disease and the evolution of the GVHD. The absence of relapse under chronic GVHD evolution further suggests an allogeneic antitumoral control. In view of the patient's previous resistance to chemotherapy, we think it is unlikely that the conditioning regimen itself could have produced such a durable response. In vitro tests demonstrating the response of lymphocytes to ovarian cancer cells could better establish the link between GVHD and regression. Unfortunately, this type of test is difficult to perform and was not done in this case.
The conditioning regimen used here is highly toxic and of little therapeutic value in patients with chemoresistance. A regimen directed toward immunosuppression rather than myeloablation such as that described by Slavin et al 6 might be better suited for therapeutic strategies that may take advantage of GVHD. According to the literature, the incidence of GVHD after using an immunosuppressive regimen may be similar, but this needs further investigation. 3, 6 Immunological strategies using IL-12 or IFN␥ have been reported to be successful in treating ovarian cancer. 4 Thus it seems reasonable that allogeneic transplantation and subsequently GVHD might have a strong anti-tumor effect. This preliminary observation favours the hypothesis of graft-versus-tumor effect in ovarian cancer. Although the particular mechanisms remain unclear and deserve further investigation, this procedure merits attention as a new therapeutic option for advanced and refractory ovarian cancer.
